Jiménez AD, Labra A, Loman ZÓA, Paz PY, Huerta DÁD, Haro VR, Sánchez NF

Language: Spanish
References: 13
Page: 174-179
PDF size: 373.12 Kb.

ABSTRACT

Background: Obstructive sleep apnea syndrome (OSAS) is present in 2-4% of adult population in the world, and about 80% of them are male. 98% of the morbid obese patients complain of OSAS symptoms, so obesity is one of the most important risk factors of OSAS, as well as tonsil hypertrophy, and they may play an important role in the severity of the respiratory condition.
Objective: To determine if body mass index and tonsil hypertrophy are related to severity of obstructive sleep apnea syndrome.
Material and method: In a retrospective trial the charts of 200 patients with diagnosis of obstructive sleep apnea syndrome −attending to the Clinic of Sleep Disorders, UNAM− were reviewed; patients were submitted to a polysomnography, assessing obstructive sleep apnea syndrome severity (mild, moderate and severe), and relating it to tonsil size and body mass index.
Results: Most patients were classified as severe obstructive sleep apnea syndrome (63%). Regarding tonsil hypertrophy, 5.5% of patients were submitted to amygdalectomy; 48% had tonsil hypertrophy stage I, 32% stage II, 14.5% stage III.
Conclusions: In the severity of obstructive sleep apnea syndrome body mass index should be taken into account as prognostic and diagnostic factor; treatment should be done in a multidisciplinary manner. Besides, obesity may be secondary to systemic problems, such as hypothyroidism and exogenous obesity.

REFERENCES

1. Valencia M, Rebollar GV, Orea TA, Castaño MA y col. Apnea del sueño en el paciente obeso. Rev Endocrinol Nutr 2001;9(2):97-102.

2. Carrillo JL, Arredondo FM, Reyes M, Castorena A y col. Síndrome de apnea obstructiva del sueño en población adulta. Neumol Cir Torax 2010;69(2):103-115.

3. Villagra SF, Villagra UJ. Apnea obstructiva del sueño. An Orl Mex 2006;51(3):129-134.

4. Rey GJ, Fernández MMC, Meijide CL, Zamarrón C y col. Prevalencia de los trastornos respiratorios del sueño y factores asociados. Aten Primaria 2007;39(5):255-259.

5. Papanas N, Steiropoulus P, Nena E, Tsara E, et al. Predictors of obstructive apnea in males with metabolic syndrome. Vasc Health Risk Manag 2010;(6):281-286.

6. Vizcarra-Escobar DR, Kawano-Castillo JF. Identificación de síntomas relacionados al síndrome de apnea obstructiva del sueño en historias clínicas de pacientes con eventos vasculares agudos. Rev Med Hered 2006;17:148-55.

7. Silverberg DS, Iaina A, Oksenberg A. Treating obstructive sleep apnea improves essential hypertension and quality of life. Am Fam Physician 2002;65(2):229-236.

8. Chobanian AV, Bakris GL, Black HR, Cushman WC, et al. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 2003;42(6):1206-1252.

9. Echevarría A, Uribe EM, Álvarez D, Giobellina R. Valor de la escala de somnolencia de Epworth en el diagnóstico de apneas obstructivas del sueño. Medicina 2000;60:902-906.

10. García X, Damiani S, Osa JL. Síndrome de apnea obstructiva del sueño. Conocimientos importantes para todo profesional de la salud. Rev Cubana Med Gen Integr 1999;15(5):562-569.

11. Sleep-related breathing disorders in adults: recommendations for syndrome definition and measurement techniques in clinical research. The Report of an American Academy of Sleep Medicine Task Force. Sleep 1999;22(5):667-689.

12. Sánchez AI, Buela CG. Assessment of daytime symptoms in snoring subjects and obstructive sleep apnea patients. Salud Mental 2007;30(1):9-15.

13. Flores C, Flores F, Bahena JA. Síndrome de apneahipopnea obstructiva del sueño (SAHOS). Med Sur 2008;15(2):100-111.